Everything below concerns LC-MS/MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
A team led by Enrico Fermi in 1934 found that bombarding uranium with neutrons produces beta rays (electrons or positrons from the elements produced; see beta particle). The fission products were at first mistaken for new elements with atomic numbers 93 and 94, which the Dean of the Sapienza University of Rome, Orso Mario Corbino, named ausenium and hesperium, respectively. The experiments leading to the discovery of uranium's ability to fission (break apart) into lighter elements and release binding energy were conducted by Otto Hahn and Fritz Strassmann in Hahn's laboratory in Berlin. Lise Meitner and her nephew, physicist Otto Robert Frisch, published the physical explanation in February 1939 and named the process "nuclear fission". Soon afterward, Fermi hypothesized that fission of uranium might release enough neutrons to sustain a fission reaction. Confirmation of this hypothesis came in 1939, and later work found that on average about 2.5 neutrons are released by each fission of uranium-235. Fermi urged Alfred O. C. Nier to separate uranium isotopes for determination of the fissile component, and on 29 February 1940, Nier used an instrument he built at the University of Minnesota to separate the world's first uranium-235 sample in the Tate Laboratory. Using Columbia University's cyclotron, John Dunning confirmed the sample to be the isolated fissile material on 1 March. Further work found that the far more common uranium-238 isotope can be transmuted into plutonium, which, like uranium-235, is also fissile by thermal neutrons.
=== STC1 === STC1 was discovered in 1995 from human kidney. It was demonstrated that human kidney extract produced the same calcium inhibitory action when injected in a fish. The gene that produce STC1, STC1 is located in the short arm of human chromosome 8 (position p21.2). STC1 mRNA is formed in heart, lung, liver, adrenal gland, prostate, and ovary, indicating that these are the sites of synthesis. Ovary contains the highest level of STC1 mRNA. Fish stanniocalcin and mammalian STC1 are closely related, and are about 50% similar in their structure. They are both responsible for calcium and phosphate balance. In mammals the predominant function of STC1 is to activate phosphate reabsorption in the small intestine and proximal tubules of the kidney.
==== Dissolution and reestablishment ==== On August 9, 2017, President Rodrigo Duterte signed Executive Order No. 38, revoking the Executive Order No. 183 signed by (former) President Benigno Aquino III on May 29 of 2015, due to the reason of the lack of funds to fully establish the NIR according to Benjamin Diokno, the Secretary of Budget and Management. Its dissolution upset the NIR regional officials and provoked strong negative reactions from the Negrenses. On June 13, 2024, Negros island together with neighboring Siquijor were grouped together under the reestablished Negros Island Region with the signing of Republic Act No. 12000 by President Bongbong Marcos.
The toxicity may also result from non-combustible sources such as the one released from anaerobic fermentation of food grains and anaerobic digestion of biodegradable waste. The World Health Organization (WHO) developed a global recommendation limiting exposures to less than 20 parts per billion for chronic exposure and value less 100 ppb for one hour for acute exposure, using nitrogen dioxide as a marker for other pollutants from fuel combustion. There is a significant association between indoor NO2 levels and increased respiratory symptoms such as wheeze, chest tightness and severity of infections among children with asthma. Historically, some cities in the United States including Chicago and Los Angeles have higher levels of nitrogen dioxide than the EPA maximum exposure limits of 100 ppb for a one-hour exposure and less than 53 ppb for chronic exposure.
== History == The existence of tRNA was first hypothesized by Francis Crick as the "adaptor hypothesis" based on the assumption that there must exist an adapter molecule capable of mediating the translation of the RNA alphabet into the protein alphabet. Paul C Zamecnik, Mahlon Hoagland, and Mary Louise Stephenson discovered tRNA in 1958. Significant research on structure was conducted in the early 1960s by Alex Rich and Donald Caspar, two researchers in Boston, the Jacques Fresco group in Princeton University and a United Kingdom group at King's College London. In 1965, Robert W. Holley of Cornell University reported the primary structure and suggested three secondary structures. tRNA was first crystallized in Madison, Wisconsin, by Robert M. Bock. The cloverleaf structure was ascertained by several other studies in the following years and was finally confirmed using X-ray crystallography studies in 1974. Two independent groups, Kim Sung-Hou working under Alexander Rich and a British group headed by Aaron Klug, published the same crystallography findings within a year.
Sources: en.wikipedia.org
The band performed three more shows, supporting Kiss on their reunion tour, with Staley's final live performance on July 3, 1996, in Kansas City, Missouri. Aside from recording two more songs with Alice in Chains – "Get Born Again" and "Died" – and a cover of Pink Floyd's "Another Brick in the Wall" with Class of '99 during 1998, Staley was out of the public spotlight by the late 1990s. Staley struggled with drug addiction and depression for much of his adult life; he later died from a speedball overdose on April 5, 2002, at the age of 34. He was ranked at No. 27 on Hit Parader's list of "Heavy Metal's All-Time Top 100 Vocalists" in 2006, and at No. 42 on Complex magazine's list of "The 50 Best Lead Singers of All Time" in 2012. Seattle officially declared August 22, 2019, as "Layne Staley Day". Staley earned six Grammy Award nominations as a member of Alice in Chains.
== Talent == Global Talent Competitiveness Index (GTCI) 2018: The report analyses the performance of 119 countries and 90 cities worldwide based on six factors: enabling talent, attracting talent, growing talent, retaining talent, vocational and technical skills, and global knowledge skills. Thailand ranked 70 of 119 countries (1=best; 119=worst). Other ASEAN nations ranked were: Singapore, 2; Philippines, 54; Indonesia, 77; Vietnam, 87; Laos, 95; and Cambodia, 108. Bangkok ranked 78 of 90 cities. Global Talent Competitiveness Index (GTCI) 2017: Thailand ranked 73 of 118 countries (1=best; 118=worst). Other ASEAN nations were ranked: Singapore, 2; Malaysia, 28; Philippines, 52; Vietnam, 86; Indonesia, 90; and Cambodia, 108. IMD World Talent Report 2016: This study purports to measure investment in and development of talent and the ability to attract and retain talent. Thailand ranked 37 of 61 nations (1=best; 61=worst), down three spots from 2015. Other ASEAN nations were ranked: Singapore, 15; Malaysia, 19; Indonesia, 44; Philippines, 51.
István Weszprémi Award, University Medical School of Debrecen (1977) Fogarty International Research Fellowship, NIH (1989–1990) Distinguished Scientist Award, Japanese Society for the Promotion of Science (1992) Pándy and Jendrassik Awards, Hungarian Society of Laboratory Medicine (1992, 2000) Széchenyi Professorial Scholarship (1997–2000) Medal for Hungarian Higher Education (1998) Medal of the Hungarian Public Health Scientific Society (2000, 2006) Albert Szent‑Györgyi Medal (2001) Hatvani Award of the City of Debrecen (2005) Semmelweis Award (2006) Öveges Professorial Scholarship (2006) Endre Hőgyes Award (2007) Leó Szilárd Professorial Scholarship (2009) Pro Auditoribus Universitatis Debreceniensis Award (2010) Pro Urbe Award of the City of Debrecen (2011) Krompecher Award, University of Debrecen (2013) Budapest Award (2013) WHO Regional Director’s Award (2019, 2023) H.R. Leavell Award, World Federation of Public Health Associations (2020) Ádám Szendei Award (2020) Officer’s Cross of the Order of Merit of Hungary (2022)
A mass-selecting quadrupole and collision quadrupole with time-of-flight device as the second mass selection stage is a hybrid known as a quadrupole time-of-flight mass spectrometer (QTOF MS). Quadrupole-quadrupole-time-of-flight (QqTOF) configurations are also possible and used especially the mass spectrometry of peptides and other large biological polymers. A variant of the quadrupole mass analyzer called the monopole was invented by von Zahn which operates with two electrodes and generates one quarter of the quadrupole field. It has one circular electrode and one V-shaped electrode. The performance is, however, lower than that of a quadrupole mass analyzer. An enhancement to the performance of the quadrupole mass analyzer has been demonstrated to occur when a magnetic field is applied to the instrument. Manifold improvements in resolution and sensitivity have been reported for a magnetic field applied in various orientations to a QMS.
== External links == WHO: Good Distribution Practices (GDP) for Pharmaceutical Products Guidelines on Good Distribution Practice of Medicinal Products for Human Use (94/C 63/03) Counterfeit Drugs (FDA) Radiofrequency Identification Feasibility Studies and Pilot Programs for Drugs (FDA) GDP Guidelines of 7 March 2013 (Eudralex) Guidelines on Good Distribution Practice (NPCB/Malaysia) GDP Guidelines of 7 March 2013 (Eudralex) How to become pharmaceutical distributor
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.